SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 241-250. Prepublished online as a Blood First Edition Paper on September 2, 2004; DOI 10.1182/blood-2004-06-2482. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-06-2482v1 105/1/241    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Powell, D. J. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by Powell, D. J., Jr Articles by Rosenberg, S. A. Related Collections Immunobiology Neoplasia Immunotherapy Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy Daniel J. Powell, Jr, Mark E. Dudley, Paul F. Robbins, and Steven A. Rosenberg From the Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. In humans, the pathways of memory T-cell differentiation remain poorly defined. Recently, adoptive cell transfer (ACT) of tumor-reactive T lymphocytes to metastatic melanoma patients after nonmyeloablative chemotherapy has resulted in persistence of functional, tumor-reactive lymphocytes, regression of disease, and induction of melanocyte-directed autoimmunity in some responding patients. In the current study, longitudinal phenotypic analysis was performed on melanoma antigen-specific CD8+ T cells during their transition from in vitro cultured effector cells to long-term persistent memory cells following ACT to 6 responding patients. Tumor-reactive T cells used for therapy were generally late-stage effector cells with a CD27Lo CD28Lo CD45RA- CD62 ligand- (CD62L-) CC chemokine receptor 7- (CCR7-) interleukin-7 receptor Lo (IL-7RLo) phenotype. After transfer, rapid up-regulation and continued expression of IL-7R in vivo suggested an important role for IL-7R in immediate and long-term T-cell survival. Although the tumor antigen-specific T-cell population contracted between 1 and 4 weeks after transfer, stable numbers of CD27+ CD28+ tumor-reactive T cells were maintained, demonstrating their contribution to the development of long-term, melanoma-reactive memory CD8+ T cells in vivo. At 2 months after transfer, melanoma-reactive T cells persisted at high levels and displayed an effector memory phenotype, including a CD27+ CD28+ CD62L- CCR7- profile, which may explain in part their ability to mediate tumor destruction. (Blood. 2005;105:241-250) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Long live T cells Laurence J. N. Cooper Blood 2005 105: 8-9. [Full Text] [PDF] This article has been cited by other articles: C. Brignone, B. Escudier, C. Grygar, M. Marcu, and F. Triebel A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma Clin. Cancer Res., October 1, 2009; 15(19): 6225 - 6231. [Abstract] [Full Text] [PDF] C. A. Klebanoff, Z. Yu, L. N. Hwang, D. C. Palmer, L. Gattinoni, and N. P. Restifo Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination Blood, August 27, 2009; 114(9): 1776 - 1783. [Abstract] [Full Text] [PDF] S. Kaneko, S. Mastaglio, A. Bondanza, M. Ponzoni, F. Sanvito, L. Aldrighetti, M. Radrizzani, S. La Seta-Catamancio, E. Provasi, A. Mondino, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes Blood, January 29, 2009; 113(5): 1006 - 1015. [Abstract] [Full Text] [PDF] T. Ando, K. Mimura, C. C. Johansson, M. G. Hanson, D. Mougiakakos, C. Larsson, T. Martins da Palma, D. Sakurai, H. Norell, M. Li, et al. Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress J. Immunol., December 15, 2008; 181(12): 8382 - 8390. [Abstract] [Full Text] [PDF] M. A. DeBenedette, D. M. Calderhead, H. Ketteringham, A. H. Gamble, J. M. Horvatinovich, I. Y. Tcherepanova, C. A. Nicolette, and D. G. Healey Priming of a Novel Subset of CD28+ Rapidly Expanding High-Avidity Effector Memory CTL by Post Maturation Electroporation-CD40L Dendritic Cells Is IL-12 Dependent J. Immunol., October 15, 2008; 181(8): 5296 - 5305. [Abstract] [Full Text] [PDF] S. Ansen, M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21 Clin. Cancer Res., October 1, 2008; 14(19): 6125 - 6136. [Abstract] [Full Text] [PDF] Y. Xiao, V. Peperzak, A. M. Keller, and J. Borst CD27 Instructs CD4+ T Cells to Provide Help for the Memory CD8+ T Cell Response after Protein Immunization J. Immunol., July 15, 2008; 181(2): 1071 - 1082. [Abstract] [Full Text] [PDF] H. Singh, P. R. Manuri, S. Olivares, N. Dara, M. J. Dawson, H. Huls, P. B. Hackett, D. B. Kohn, E. J. Shpall, R. E. Champlin, et al. Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System Cancer Res., April 15, 2008; 68(8): 2961 - 2971. [Abstract] [Full Text] [PDF] C. L. Montes, A. I. Chapoval, J. Nelson, V. Orhue, X. Zhang, D. H. Schulze, S. E. Strome, and B. R. Gastman Tumor-Induced Senescent T Cells with Suppressor Function: A Potential Form of Tumor Immune Evasion Cancer Res., February 1, 2008; 68(3): 870 - 879. [Abstract] [Full Text] [PDF] B. Savoldo, C. M. Rooney, A. Di Stasi, H. Abken, A. Hombach, A. E. Foster, L. Zhang, H. E. Heslop, M. K. Brenner, and G. Dotti Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease Blood, October 1, 2007; 110(7): 2620 - 2630. [Abstract] [Full Text] [PDF] M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell Clin. Cancer Res., March 15, 2007; 13(6): 1857 - 1867. [Abstract] [Full Text] [PDF] L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al. Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration Clin. Cancer Res., January 15, 2007; 13(2): 644 - 653. [Abstract] [Full Text] [PDF] X. Zhang, H. Dong, W. Lin, S. Voss, L. Hinkley, M. Westergren, G. Tian, D. Berry, D. Lewellen, R. G. Vile, et al. Human Bone Marrow: A Reservoir for "Enhanced Effector Memory" CD8+ T Cells with Potent Recall Function J. Immunol., November 15, 2006; 177(10): 6730 - 6737. [Abstract] [Full Text] [PDF] D. J. Powell Jr., M. E. Dudley, K. A. Hogan, J. R. Wunderlich, and S. A. Rosenberg Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion J. Immunol., November 1, 2006; 177(9): 6527 - 6539. [Abstract] [Full Text] [PDF] C. Smith, L. Cooper, M. Burgess, M. Rist, N. Webb, E. Lambley, J. Tellam, P. Marlton, J. F. Seymour, M. Gandhi, et al. Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope J. Immunol., October 1, 2006; 177(7): 4897 - 4906. [Abstract] [Full Text] [PDF] J. Huang, K. W. Kerstann, M. Ahmadzadeh, Y. F. Li, M. El-Gamil, S. A. Rosenberg, and P. F. Robbins Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy. J. Immunol., June 15, 2006; 176(12): 7726 - 7735. [Abstract] [Full Text] [PDF] A. Bondanza, V. Valtolina, Z. Magnani, M. Ponzoni, K. Fleischhauer, M. Bonyhadi, C. Traversari, F. Sanvito, S. Toma, M. Radrizzani, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes Blood, March 1, 2006; 107(5): 1828 - 1836. [Abstract] [Full Text] [PDF] A. Song, X. Tang, K. M. Harms, and M. Croft OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen J. Immunol., September 15, 2005; 175(6): 3534 - 3541. [Abstract] [Full Text] [PDF] S. Coleman, A. Clayton, M. D. Mason, B. Jasani, M. Adams, and Z. Tabi Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer Cancer Res., August 1, 2005; 65(15): 7000 - 7006. [Abstract] [Full Text] [PDF] C. A. Klebanoff, L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A. R. Cardones, S. E. Finkelstein, D. C. Palmer, P. A. Antony, S. T. Hwang, S. A. Rosenberg, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells PNAS, July 5, 2005; 102(27): 9571 - 9576. [Abstract] [Full Text] [PDF] A. Takahashi, M. G. V. Hanson, H. R. Norell, A. M. Havelka, K. Kono, K.-J. Malmberg, and R. V. R. Kiessling Preferential Cell Death of CD8+ Effector Memory (CCR7-CD45RA-) T Cells by Hydrogen Peroxide-Induced Oxidative Stress J. Immunol., May 15, 2005; 174(10): 6080 - 6087. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020